CEO Ian Akash Morrison Leads Winning Presentation Showcasing Translational Oncology Platform
Los Angeles, CA – 2025 — Avesta Bio, a translational oncology company developing first-in-class therapies targeting fundamental cellular stress-response and drug-resistance pathways, was awarded First Place at the 2025 BioScienceLA Startup Pitch Competition. The winning presentation was delivered by CEO and Co-Founder Ian Akash Morrison.
The BioScienceLA Startup Pitch Competition is a prominent showcase of emerging life sciences companies across the Greater Los Angeles region. The event convenes investors, industry executives, academic leaders, and biotechnology innovators to evaluate high-potential early-stage companies advancing novel therapeutic platforms.
Mr. Morrison’s presentation highlighted Avesta Bio’s mechanistically driven approach to targeting maladaptive stress-response pathways implicated in tumor progression and drug resistance. The pitch outlined the company’s translational strategy, regulatory pathway, and plans to advance its lead oncology program toward Phase I clinical development.
The judging panel evaluated companies based on scientific rigor, clinical and commercial potential, strategic clarity, and overall execution. Avesta Bio was recognized for the strength of its underlying science, its defined development roadmap, and its disciplined approach to advancing first-in-class oncology therapeutics.
“This recognition reflects the depth of the scientific foundation underlying our platform and the commitment of our team,” said Ian Akash Morrison, CEO of Avesta Bio. “We are focused on translating decades of stress-response biology research into safe and effective therapies for patients with high-unmet-need cancers.”
Winning First Place at BioScienceLA further positions Avesta Bio within the Southern California biotechnology ecosystem as the company continues to build strategic relationships across manufacturing, regulatory, and clinical development partners.
About Avesta Bio
Avesta Bio is a translational oncology company developing first-in-class therapies that target fundamental cellular stress-response and drug-resistance pathways. By correcting maladaptive cellular programs implicated in cancer progression, the company aims to deliver safe and effective treatments for patients with high-unmet-need malignancies.
The company is advancing its lead therapeutic program toward Phase I clinical evaluation through global partnerships in IND-enabling studies, GMP manufacturing, and clinical development.
For more information, visit: www.avestabio.com